Remove Licensing Remove Pharmaceuticals Remove Regulations
article thumbnail

Trends in Pharmaceutical Mergers and Acquisitions

DrugBank

Deal Structuring Deal structuring in pharmaceutical M&A requires a balance of financial, legal, and strategic considerations. However, ensuring that these structures comply with applicable tax laws and regulations is essential to avoid potential legal and reputational risks.

article thumbnail

Hyman, Phelps & McNamara, P.C. (HP&M) is Pleased to Announce the Addition of Sara M. Keup as the new State Licensing Regulatory Expert for the Firm’s Licensing Practice

FDA Law Blog: Biosimilars

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years. Keup has joined the firm to assist attorneys Karla L.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate

The Pharma Data

Teva Pharmaceutical Industries Ltd. NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Teva Pharmaceutical Industries Ltd. About Teva.

article thumbnail

Navigating the Challenges and Opportunities of the PICO Framework in the New EU HTA Regulation

PPD

The European Union (EU) is on the verge of a significant shift as it prepares to implement new health technology assessment (HTA) regulations in 2025. Challenges and opportunities of the new EU HTA regulation The implementation of centralized HTA presents both opportunities and challenges for pharmaceutical companies.

article thumbnail

The future of mental health treatment: Zelquistinel’s role

Drug Target Review

Neuropsychiatric disorders, affecting millions worldwide, disrupt the brain’s intricate processes of mood regulation, cognition and behaviour. Advancing drug candidates across key therapeutic areas Dr John Donello brings over 25 years of experience in pharmaceutical drug discovery, development and collaborations.

article thumbnail

Biotech leader champions targeted cancer treatments and diversity

Drug Target Review

At this point, I knew that I wanted to join the biotech and pharmaceutical industry, so I moved to a small biotech company in London, where I spent three to four years learning the fundamentals of the biotech industry. Personally, I went from working in licensing and business development in big pharma straight to being a CEO.

article thumbnail

Obesity care gets personalised: tailoring therapies with Phenomix

Drug Target Review

The MyPhenome test has already gained traction among obesity specialists, particularly in Chicago and Florida, and Phenomix has formed strategic partnerships with multiple pharmaceutical companies to support clinical trials and further analyse obesity-related data.